BRCA1 and breast carcinoma: Concerns regarding acquired resistance have been noted using PARPi in breast cancer with BRCA1/2 mutations where the overexpression of drug-efflux transporters and the occurrence of reverse mutations may lead to the reactivation of BRCA1/2 function and the restoration of the homologous recombination repair pathway (Barchiesi et al., 2021; Tung and Garber, 2022).